1SO2

CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.277 
  • R-Value Work: 0.232 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Crystal Structure of Human Phosphodiesterase 3B: Atomic Basis for Substrate and Inhibitor Specificity

Scapin, G.Patel, S.B.Chung, C.Varnerin, J.P.Edmondson, S.D.Mastracchio, A.Parmee, E.R.Singh, S.B.Becker, J.W.Van Der Ploeg, L.H.Tota, M.R.

(2004) Biochemistry 43: 6091-6100

  • DOI: 10.1021/bi049868i
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide signaling and as such are clinical targets for a range of disorders including congestive heart failure, erectile dysfunction, and inflammation. The PDE3 family comprises two highly ...

    Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide signaling and as such are clinical targets for a range of disorders including congestive heart failure, erectile dysfunction, and inflammation. The PDE3 family comprises two highly homologous subtypes expressed in different tissues, and inhibitors of this family have been shown to increase lipolysis in adipocytes. A specific PDE3B (the lipocyte-localized subtype) inhibitor would be a very useful tool to evaluate the effects of PDE3 inhibition on lipolysis and metabolic rate and might become a novel tool for treatment of obesity. We report here the three-dimensional structures of the catalytic domain of human PDE3B in complex with a generic PDE inhibitor and a novel PDE3 selective inhibitor. These structures explain the dual cAMP/cGMP binding capabilities of PDE3, provide the molecular basis for inhibitor specificity, and can supply a valid platform for the design of improved compounds.


    Organizational Affiliation

    Departments of Medicinal Chemistry, Merck & Co., Rahway, New Jersey 07065, USA. giovanna_scapin@merck.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
cGMP-inhibited 3',5'-cyclic phosphodiesterase B
A, B, C, D
420Homo sapiensMutation(s): 0 
Gene Names: PDE3B
EC: 3.1.4.17
Find proteins for Q13370 (Homo sapiens)
Go to Gene View: PDE3B
Go to UniProtKB:  Q13370
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
666
Query on 666

Download SDF File 
Download CCD File 
A, B, C, D
6-(4-{[2-(3-IODOBENZYL)-3-OXOCYCLOHEX-1-EN-1-YL]AMINO}PHENYL)-5-METHYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE
(5R)-6-(4-{[2-(3-IODOBENZYL)-3-OXOCYCLOHEX-1-EN-1-YL]AMINO}PHENYL)-5-METHYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE
C24 H24 I N3 O2
QNURTFDBHAQRSI-OAHLLOKOSA-N
 Ligand Interaction
HG9
Query on HG9

Download SDF File 
Download CCD File 
A, B
1-DEOXY-1-[(2-HYDROXYETHYL)(NONANOYL)AMINO]HEXITOL
HG9A-9, NONANOYL-N-HYDROXYETHYLGLUCAMIDE
C17 H35 N O7
REPLXGVUTGZQCG-WTTBNOFXSA-N
 Ligand Interaction
MG
Query on MG

Download SDF File 
Download CCD File 
A, B, C, D
MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
666IC50: 0.1 - 0.3 nM (100) BINDINGDB
666IC50: 0.27 nM BINDINGMOAD
666IC50: 0.27 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.277 
  • R-Value Work: 0.232 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 147.482α = 90.00
b = 121.772β = 100.74
c = 126.671γ = 90.00
Software Package:
Software NamePurpose
MOLREPphasing
CNXrefinement
HKL-2000data reduction
SCALEPACKdata scaling
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2004-05-11
    Type: Initial release
  • Version 1.1: 2008-04-29
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance